Literature DB >> 19582179

Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy.

A Daniilidis1, V Karagiannis.   

Abstract

Epithelial ovarian cancer is the seventh most frequent cancer in European women. Many theories have been postulated regarding the pathogenesis of ovarian cancer. Risk factors are not well defined, with the exception of low parity and oral contraceptive use. Approximately 10% of ovarian cancer are hereditary, with BRCA1 and BRCA2 explaining the majority (approximately 90%) of hereditary ovarian cancer cases. The lifetime risk varies between 15 and 66%, suggesting the existence of modifying genetic or environmental factors.Family history can be used to define women who are at increased risk of ovarian cancer. Individuals at high risk are those with a first degree relative (mother, father, sister, brother, daughter or son) affected by cancer. It must be noted that currently available tests do not attain the aforementioned high level of sensitivity. Evidence suggest that presymptomatic screening by grey scale ultrasound (with or without Doppler), CA125, pelvic examination, or combinations of these, are not effective in detecting tumors at an early stage. Women identified as being at high risk of ovarian cancer can be offered prophylactic oophorectomy. The decision whether or not to proceed to prophylactic oophorectomy is influenced by the fact that most women at increased risk of ovarian cancer are also at increased risk of breast cancer and there is evidence that oophorectomy reduces breast cancer in these cases.

Entities:  

Keywords:  CA125; hereditary cancer; prophylactic oophorectomy

Year:  2007        PMID: 19582179      PMCID: PMC2464274     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  33 in total

1.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacob; M J Thun
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents.

Authors:  Cristina Rodríguez-Burford; Mack N Barnes; Denise K Oelschlager; Russell B Myers; Lynya I Talley; Edward E Partridge; William E Grizzle
Journal:  Clin Cancer Res       Date:  2002-01       Impact factor: 12.531

3.  Symptomatology of ovarian cancer.

Authors:  F Flam; N Einhorn; K Sjövall
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1988-01       Impact factor: 2.435

4.  Aspirin and epithelial ovarian cancer.

Authors:  A Akhmedkhanov; P Toniolo; A Zeleniuch-Jacquotte; I Kato; K L Koenig; R E Shore
Journal:  Prev Med       Date:  2001-12       Impact factor: 4.018

5.  Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay.

Authors:  L Taylor; H Schwarz
Journal:  J Immunol Methods       Date:  2001-09-01       Impact factor: 2.303

6.  Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.

Authors:  B Y Karlan; R L Baldwin; E Lopez-Luevanos; L J Raffel; D Barbuto; S Narod; L D Platt
Journal:  Am J Obstet Gynecol       Date:  1999-04       Impact factor: 8.661

7.  Symptoms of ovarian cancer.

Authors:  S H Olson; L Mignone; C Nakraseive; T A Caputo; R R Barakat; S Harlap
Journal:  Obstet Gynecol       Date:  2001-08       Impact factor: 7.661

8.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

9.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 10.  Risk factors and risk reduction of breast and ovarian cancer.

Authors:  Cecile T M Brekelmans
Journal:  Curr Opin Obstet Gynecol       Date:  2003-02       Impact factor: 1.927

View more
  3 in total

1.  Betulinic Acid Suppresses Ovarian Cancer Cell Proliferation through Induction of Apoptosis.

Authors:  Dahae Lee; Seoung Rak Lee; Ki Sung Kang; Yuri Ko; Changhyun Pang; Noriko Yamabe; Ki Hyun Kim
Journal:  Biomolecules       Date:  2019-07-03

Review 2.  Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.

Authors:  Talha Bin Emran; Asif Shahriar; Aar Rafi Mahmud; Tanjilur Rahman; Mehedy Hasan Abir; Mohd Faijanur-Rob Siddiquee; Hossain Ahmed; Nova Rahman; Firzan Nainu; Elly Wahyudin; Saikat Mitra; Kuldeep Dhama; Mahmoud M Habiballah; Shafiul Haque; Ariful Islam; Mohammad Mahmudul Hassan
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer.

Authors:  Xibiao Jia; Xiaogang Liu; Ming Li; Yu Zeng; Zaoming Feng; Xian Su; Yan Huang; Maomao Chen; Xueyi Yang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.